|
AutoGenomics is mapping the road to the future of medicine. The company developed a genetic testing system called INFINITI that scans DNA samples for genetic disorders, infectious diseases, cancer, and pharmacogenetics (a patient's genetic likeliness to have an adverse reaction to a drug). AutoGenomics found about 25 uses for the INFINITI, but only four have been approved by the FDA for diagnostic use -- testing for sensitivity to the popular blood thinner warfarin, screening for the risk of developing cystic fibrosis or cervical cancer (for women with HPV), and testing for a gene that blocks common drugs from working. AutoGenomics was founded in 1999 as Neuron Technologies and applied to go public in 2008.
|
| | | Contact Information | |
Address: |
2251 Rutherford Rd.
Carlsbad, CA 92008
| | Phone: | 760-804-7378 | | Fax: | 760-804-7382 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2007): | 1.60 M | | Revenue Growth (1 yr): | 221.40% | | Employees (2007): | 103 |
|
|
Key People
| | • |
Chairman, President, and CEO:
Fareed Kureshy
| | • |
COO, CFO, Secretary, and Director:
Thomas V. Hennessey Jr.
| | • |
SVP, Sales and Marketing:
Ramanath (Ram) Vairavan
|
|
|
